Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
6 Articles
6 Articles
Hastings Tribune
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD)Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study…
Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMD REYKJAVIK, Iceland […] The post Adv…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
